DNA damage response (DDR) deficiencies result in genome instability, which is one of the hallmarks of cancer. Poly (ADP-ribose) polymerase (PARP) enzymes take part in various DDR pathways, determining cell fate in the wake of DNA damage. PARPs are readily druggable and PARP inhibitors (PARPi) against the main DDR-associated PARPs, PARP1 and PARP2, are currently approved for the treatment of a range of tumor types. Inhibition of efficient PARP1/2-dependent DDR is fatal for tumor cells with homologous recombination deficiencies (HRD), especially defects in breast cancer type 1 susceptibility protein 1 or 2 (BRCA1/2)-dependent pathway, while allowing healthy cells to survive. Moreover, PARPi indirectly influence the tumor microenvironment by increasing genomic instability, immune pathway activation and PD-L1 expression on cancer cells. For this reason, PARPi might enhance sensitivity to immune checkpoint inhibitors (ICIs), such as anti-PD-(L)1 or anti-CTLA4, providing a rationale for PARPi-ICI combination therapies. In this review, we discuss the complex background of the different roles of PARP1/2 in the cell and summarize the basics of how PARPi work from bench to bedside. Furthermore, we detail the early data of ongoing clinical trials indicating the synergistic effect of PARPi and ICIs. We also introduce the diagnostic tools for therapy development and discuss the future perspectives and limitations of this approach.
Background/Objectives: Chronic kidney disease is more prevalent among women, and there are significant disparities in the management of female patients. Our study aimed to assess the clinical experience and educational needs of physicians in the treatment of reproductive and sex and gender-related health problems in patients with CKD. Methods: The three-part survey was distributed among nephrologists and other internal medicine specialists in Poland, both online and in paper form. Results: A total of 116 physicians participated in the survey, including 81 nephrologists. Most respondents (64.7%) were female and practiced in multispecialty hospitals (72.4%). While 97.4% managed patients with CKD, only 37.9% reported caring for pregnant women. Experience in sex-specific and pregnancy-related issues was limited—56.9% reported low or minimal experience in managing CKD during pregnancy. Residency training lacked coverage of crucial topics, with 66.2% reporting limited teaching on sex-related CKD progression. Over 90% supported integrating reproductive planning and interdisciplinary care into nephrology, favoring guidelines, conferences, and webinars for education. Conclusions: Our study has highlighted a critical discrepancy between the importance of sex-specific and reproductive health considerations in the management of CKD and the current level of clinical experience among Polish doctors.